1. Academic Validation
  2. The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp function

The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp function

  • Int J Oncol. 2011 Mar;38(3):701-11. doi: 10.3892/ijo.2010.888.
Lilly Chai 1 Rajashree P McLaren Ann Byrne Wei-Lien Chuang Yinyin Huang Michael R Dufault Joshua Pacheco Shruti Madhiwalla Xiaokui Zhang Mindy Zhang Beverly A Teicher Kara Carter Seng H Cheng John P Leonard Yibin Xiang Michael Vasconcelles Mark A Goldberg Diane P Copeland Katherine W Klinger James Lillie Stephen L Madden Yide A Jiang
Affiliations

Affiliation

  • 1 Genzyme Corporation, Framingham, MA 01701, USA.
Abstract

Glucosylceramide synthase (GCS) is a key Enzyme engaged in the biosynthesis of glycosphingolipids and in regulating ceramide metabolism. Studies exploring alterations in GCS activity suggest that the glycolase may have a role in chemosensitizing tumor cells to various Cancer drugs. The chemosensitizing effect of inhibitors of GCS (e.g. PDMP and selected analogues) has been observed with a variety of tumor cells leading to the proposal that the sensitizing activity of GCS inhibitors is primarily through increases in intracellular ceramide leading to induction of Apoptosis. The current study examined the chemosensitizing activity of the novel GCS inhibitor, Genz-123346 in Cell Culture. Exposure of cells to Genz-123346 and to other GCS inhibitors at non-toxic concentrations can enhance the killing of tumor cells by cytotoxic anti-cancer agents. This activity was unrelated to lowering intracellular glycosphingolipid levels. Genz-123346 and a few other GCS inhibitors are substrates for multi-drug resistance efflux pumps such as P-gp (ABCB1, gP-170). In cell lines selected to over-express P-gp or which endogenously express P-gp, chemosensitization by Genz-123346 was primarily due to the effects on P-gp function. RNA interference studies using siRNA or shRNA confirmed that lowering GCS expression in tumor cells did not affect their responsiveness to commonly used cytotoxic drugs.

Figures
Products